Aptose Biosciences Book Value 2011-2026 | APTO

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Aptose Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-4.54 M	-2.9 M	37.7 M	74.2 M	119 M	93.9 M	14.1 M	10.2 M	7.32 M	13.6 M	26.2 M	-758 K	-1.97 M	865 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
119 M	-4.54 M	27.6 M

Quarterly Book Value Aptose Biosciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-19.4 M	-14.4 M	-7.39 M	-4.54 M	-	-2.18 M	137 K	-2.9 M	7.78 M	13.8 M	26 M	37.7 M	46.8 M	-	65.3 M	74.2 M	88.7 M	98.2 M	109 M	119 M	119 M	119 M	119 M	93.9 M	93.9 M	93.9 M	93.9 M	14.1 M	14.1 M	14.1 M	14.1 M	12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
119 M	-19.4 M	47.9 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Adaptimmune Therapeutics plc ADAP	39.5 M	-	-15.15 %	$ 60.3 M	Britain
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
ANI Pharmaceuticals ANIP	429 M	$ 80.34	-	$ 1.55 B	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Aptorum Group Limited APM	11.8 M	$ 0.84	1.96 %	$ 4.58 M	China
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Adagene ADAG	50.5 M	$ 2.67	-	$ 150 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.57	-	$ 8.59 B	Australia
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Aeglea BioTherapeutics AGLE	518 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	-30.6 M	$ 1.5	-	$ 281 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-106 M	$ 222.03	-	$ 5 B	Danmark
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	19.4 B	$ 110.34	-	$ 27.2 B	Germany
Cabaletta Bio CABA	236 M	$ 2.44	-	$ 2.85 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Aridis Pharmaceuticals ARDS	-24.2 M	-	17.91 %	$ 11.1 M	USA
Burford Capital Limited BUR	1.66 B	$ 8.97	-	$ 1.44 B	Britain
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 4.22	-	$ 9.18 B	Israel
Autolus Therapeutics plc AUTL	427 M	$ 1.46	-	$ 373 M	Britain
Compugen Ltd. CGEN	132 M	$ 1.71	-	$ 153 M	Israel
Amneal Pharmaceuticals AMRX	3.5 B	$ 14.52	-	$ 4.49 B	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel